A study has revealed similar patterns of non-compliance across different countries and calls into question the actual scope of supervision

consalud.es

A recent analysis published in the international scientific literature focuses on FDA inspections and the agency’s ability to oversee the quality of clinical trials globally, highlighting both their significance and their limitations.

The study, based on open-access data from inspections carried out by the US agency, concludes that only a small fraction of clinical trials worldwide are inspected directly by the FDA, reflecting a limited scope in the face of the exponential growth of international clinical research.

Despite this limited coverage, the results show a consistent pattern: the deficiencies detected during inspections are similar regardless of geographical region. Among the most frequent problems are failures to comply with protocols, deficiencies in documentation and errors in the management of clinical data.

The shortcomings identified during inspections are similar regardless of the geographical region

FDA inspections form part of its monitoring programme, which aims to verify the reliability of data and ensure patient safety. These may be carried out routinely or for specific reasons, such as suspected irregularities or inconsistencies in the results.

During these audits, inspectors review clinical records, informed consent procedures, adherence to protocols and the traceability of the treatments under investigation. Furthermore, they may issue formal observations when they detect potential regulatory non-compliance.

The nature of the issues identified is remarkably similar across the globe

The analysis also highlights that, although the number of inspections varies significantly between regions, the nature of the issues identified is remarkably similar across the globe, suggesting structural challenges in the conduct of clinical trials rather than isolated failures.

These findings are particularly relevant in a context where clinical trials are becoming increasingly complex and globalised. The FDA remains an international benchmark in regulatory matters, but the study highlights the need to strengthen oversight mechanisms to ensure quality and transparency in the development of new medicines.

Ultimately, the study highlights that, beyond the number of inspections, the main challenge lies in improving compliance standards and ensuring that the clinical data underpinning the approval of treatments are robust, reliable and representative on a global scale.